{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Progression free survival (PFS) rate will be calculated from the time of randomization to first evidence of disease recurrence or death of any cause.","groups":[{"description":"Galinpepimut-S + Montanide + GM-CSF","id":"OG000","title":"Galinpepimut-S"},{"description":"Montanide + GM-CSF","id":"OG001","title":"Control"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"1-year Progression-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}